CTNM Company Profile and Key Details

CTNM has shown mixed momentum, gaining 29.23% over the past week and 1.28% over the past quarter, though year-to-date performance is up 3.67%. Short-term trend indicators are bearishly aligned (SMA20 4.18%, SMA50 21.25%, SMA200 66.58%). The stock’s 14-day RSI is 63.4 (firm momentum), while the ATR of 0.93 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.37% below its high and over 371.04% above its low. Average 10-day trading volume of 320.46 thousand shares is below the 3-month average of 436.28 thousand, indicating normal recent market interest.

Contineum Therapeutics, Inc. has 32.96 million shares outstanding. The public float is 27.82 million shares, elevated short interest at 8.61% of float. This equals 2.82 million shares. The short ratio is 9.8 days. Institutional investors hold 93.0% of the float. Insiders own 0.53%. Lorrain Daniel S. holds 135.20 thousand shares, Stengone Carmine N. has 17.22 thousand shares and Watkins Tim has 8.96 thousand shares. Over the past six months, insider transactions show net selling. They sold 68.32 thousand shares across 11 transactions.

Wall Street analysts project EPS growth of 1.35% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $16.00. The high target offers 51.92% upside. The low target suggests 5.68% downside. The mean target is $20.00. This offers 32.1% upside. Contineum Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended July 30, 2026, missed forecasts by -13.04%. The prior quarter beat by -29.09%. Over the last six quarters, Apple has recorded several small beats. These include 10.71% in May 14, 2025.

Contineum Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.43. This means the shares are trading above this model’s fair value.

Contineum Therapeutics, Inc. (NASDAQ:CTNM) closed at $15.14 USD, losing -$0.80 (-5.02%) from the previous close of $15.94. The stock is currently mid-range between its 52-week high and low $8.60 and $17.79. With a market capitalization of about $569.58 million, Contineum Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.75). Key stats such as the average daily volume over the past year has been around 441.01 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Contineum Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carmine N. Stengone, the company employs approximately 51 people and listed since April 04, 2024. Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.

Contineum Therapeutics, Inc. trades at a P/E ratio of -8.89, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.4 suggesting the stock is closer to book value. The P/FCF stands at -10.82, also below market averages.

Our AI price prediction model suggests that Contineum Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.91%, with price expected at $16.64 by September 23, 2026, within a range of $15.79 to $17.43 3-Month Outlook: Projected fall of -26.95%, reaching $11.06 by December 07, 2026, with a range of $10.77 to $11.39. 1-Year Outlook: Projected loss of -9.51%, with price at $13.70 by September 09, 2027, within a range of $11.99 to $15.48.

Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are flat 3.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Contineum Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.89. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $22.15, suggesting 46.3% upside. Our AI forecast model points to short-term strength (9.91% over two weeks), a medium-term fall (-26.95% over three months), and a longer-term loss (-9.51% over one year), with expected trading ranges indicating moderate volatility.